Effect of Lidocaine in Reducing Opioids Requirement in Day Care Surgery

NCT ID: NCT06717672

Last Updated: 2024-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-05

Study Completion Date

2024-05-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. \*Reduced opioid consumption
2. \*Decreased pain scores
3. \*Fewer opioid-related side effects
4. \*Improved patient satisfaction

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Studies have shown that lidocaine can reduce opioid consumption by 20-50% in the perioperative period.

Studies have shown that lidocaine can reduce opioid consumption by 20-50% in the perioperative period.

By reducing opioid consumption, lidocaine can also decrease the incidence of opioid-related side effects, such as nausea, vomiting, and respiratory depression.

Lidocaine's analgesic effects can improve patient satisfaction and reduce anxiety related to pain

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Post-operative Pain Control Post-operative Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Lidocaine Opiods Peri-operative pain Decrease Opioid requirement Ambulatory surgeries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

intervention group recieve inj lidocaine

Group Type ACTIVE_COMPARATOR

Lidocaine 2% without vessel constrictor

Intervention Type DRUG

1. \_Lidocaine 2% provides rapid and effective local anesthesia for minor surgical procedures, such as biopsies, excisions, and suturing.
2. \_Pain relief\_: Lidocaine 2% has been shown to provide significant pain relief in patients with acute pain, such as post-operative pain, trauma, and burns.
3. \_Reducing pain intensity\_: Lidocaine 2% has been shown to reduce pain intensity by 30-50% in various clinical studies.

Control group

control group receive Normal saline

Group Type PLACEBO_COMPARATOR

Normal Saline

Intervention Type DRUG

Normal saline used is an iv fluid given for fluid replacement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine 2% without vessel constrictor

1. \_Lidocaine 2% provides rapid and effective local anesthesia for minor surgical procedures, such as biopsies, excisions, and suturing.
2. \_Pain relief\_: Lidocaine 2% has been shown to provide significant pain relief in patients with acute pain, such as post-operative pain, trauma, and burns.
3. \_Reducing pain intensity\_: Lidocaine 2% has been shown to reduce pain intensity by 30-50% in various clinical studies.

Intervention Type DRUG

Normal Saline

Normal saline used is an iv fluid given for fluid replacement

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA 1 and 2
* patient age between 18 and 65 years
* Patient undergoing ambulatory surgeries

Exclusion Criteria

* Pregnant women
* Allergic to Lidocaine Patient who had fever and treated with antibiotic and steroid in last month
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Liaquat National Hospital & Medical College

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hanesh Tanwani

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hanesh Tanwani Dr Hanesh Tanwani

Role: PRINCIPAL_INVESTIGATOR

Liaquat National Hospital and Medical College

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Liaquat National Hospital and Medical College

Karachi, Sindh, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Related Links

Access external resources that provide additional context or updates about the study.

https://pubmed.ncbi.nlm.nih.gov/19923506/

Systemic lidocaine decreased the perioperative opioid analgesic requirements but failed to reduce discharge time after ambulatory surgery Allannah McKay 1, Antje Gottschalk, Annette Ploppa, Marcel E Durieux, Danja S Groves

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ANS-2021-192-2750

Identifier Type: -

Identifier Source: org_study_id